About this Journal Submit a Manuscript Table of Contents
ISRN Rheumatology
Volume 2013 (2013), Article ID 215034, 6 pages
http://dx.doi.org/10.1155/2013/215034
Review Article

Oral Bisphosphonate Related Osteonecrosis of the Jaw: A Challenging Adverse Effect

Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Cukurova University, Adana 01330, Turkey

Received 8 April 2013; Accepted 1 May 2013

Academic Editors: P. Voulgari and L. Xing

Copyright © 2013 Ilke Coskun Benlidayi and Rengin Guzel. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Z. Janovská, “Bisphosphonate-related osteonecrosis of the jaws. A severe side effect of bisphosphonate therapy,” Acta Medica, vol. 55, no. 3, pp. 111–115, 2012.
  2. M. Diniz-Freitas, J. L. López-Cedrún, J. Fernández-Sanromán, et al., “Oral bisphosphonate-related osteonecrosis of the jaws: clinical characteristics of a series of 20 cases in Spain,” Medicina Oral , Patología Oral y Cirugía Bucal, vol. 17, no. 5, pp. e751–e758, 2012.
  3. S. L. Ruggiero, “Guidelines for the diagnosis of bisphosphonate-related osteonecrosis of the jaw (BRONJ),” Clinical Cases in Mineral and Bone Metabolism, vol. 4, no. 1, pp. 37–42, 2007. View at Scopus
  4. R. E. Marx, “Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic,” Journal of Oral and Maxillofacial Surgery, vol. 61, no. 9, pp. 1115–1117, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. C. A. Migliorati, “Bisphosphanates and oral cavity avascular bone necrosis,” Journal of Clinical Oncology, vol. 21, no. 22, pp. 4253–4254, 2003. View at Scopus
  6. B. Mehrotra, J. Fantasia, S. N. Horrowitz, et al., “Osteonecrosis of the maxilla, an unusual complication of prolonged bisphosphonate therapy: a case report,” Proceedings of the American Society of Clinical Oncology, vol. 22, article 795, 2003.
  7. T. J. Rosenberg and S. Ruggiero, “Osteonecrosis of the jaw associated with the use of bisphosphonates,” Journal of Oral and Maxillofacial Surgery, vol. 61, supplement 1, article 60, 2003.
  8. I. Dimitrakopoulos, C. Magopoulos, and D. Karakasis, “Bisphosphonate-induced avascular osteonecrosis of the jaws: a clinical report of 11 cases,” International Journal of Oral and Maxillofacial Surgery, vol. 35, no. 7, pp. 588–593, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. M. H. Vieillard, J. M. Maes, G. Penel et al., “Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapy,” Joint Bone Spine, vol. 75, no. 1, pp. 34–40, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. C. L. Estilo, C. H. van Posnak, T. Williams, et al., “Osteonecrosis of the maxilla and mandible in patients treated with bisphosphonates: a retrospective study,” Journal of Clinical Oncology, vol. 22, article 8088a, 2004.
  11. J. V. Bagan, Y. Jimenez, J. Murillo et al., “Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases,” Oral Oncology, vol. 42, no. 3, pp. 327–329, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws and American Association of Oral and Maxillofacial Surgeons, “American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws,” Journal of Oral and Maxillofacial Surgery, vol. 65, no. 3, pp. 369–376, 2007.
  13. G. Colella, G. Campisi, and V. Fusco, “Association of Oral and Maxillofacial Surgeons position paper: bisphosphonaterelated osteonecrosis of the jaws-2009 update, the need to refine the BONJ definition,” Journal of Oral and Maxillofacial Surgery, vol. 67, no. 12, pp. 2698–2699, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. N. M. McLeod, P. A. Brennan, and S. L. Ruggiero, “Bisphosphonate osteonecrosis of the jaw: a historical and contemporary review,” Surgeon, vol. 10, no. 1, pp. 36–42, 2012.
  15. S. L. Ruggiero, T. B. Dodson, L. A. Assael, R. Landesberg, R. E. Marx, and B. Mehrotra, “American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw—2009 update,” Australian Endodontic Journal, vol. 35, no. 3, pp. 119–130, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Mavrokokki, A. Cheng, B. Stein, and A. Goss, “Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia,” Journal of Oral and Maxillofacial Surgery, vol. 65, no. 3, pp. 415–423, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Ault, “Jaw necrosis affects 1 in 1, 700 on oral bisphosphonates,” Internal Medicine News, vol. 41, article 23, 2008.
  18. P. P. Sedghizadeh, K. Stanley, M. Caligluri, S. Hofkes, B. Lowry, and C. F. Shuler, “Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry,” Journal of the American Dental Association, vol. 140, no. 1, pp. 61–66, 2009. View at Scopus
  19. J. W. Hong, W. Nam, I. H. Cha et al., “Oral bisphosphonate-related osteonecrosis of the jaw: the first report in Asia,” Osteoporosis International, vol. 21, no. 5, pp. 847–853, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Otto, M. H. Abu-Id, S. Fedele et al., “Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: not just a sporadic coincidence—a multi-centre study,” Journal of Cranio-Maxillofacial Surgery, vol. 39, no. 4, pp. 272–277, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. T. Yamazaki, M. Yamori, K. Yamamoto, et al., “Risk of osteomyelitis of the jaw induced by oral bisphosphonates in patients taking medications for osteoporosis: a hospital-based cohort study in Japan,” Bone, vol. 51, no. 5, pp. 882–887, 2012.
  22. R. E. Marx, J. E. Cillo Jr., and J. J. Ulloa, “Oral bisphosphonate-induced osteonecrosis:risk factors, prediction of risk using serum CTX testing, prevention, and treatment,” Journal of Oral and Maxillofacial Surgery, vol. 65, no. 12, pp. 2397–2410, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. P. K. Palaska, V. Cartsos, and A. I. Zavras, “Bisphosphonates and time to osteonecrosis development,” Oncologist, vol. 14, no. 11, pp. 1154–1166, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. L. M. Hess, J. M. Jeter, M. Benham-Hutchins, and D. S. Alberts, “Factors associated with osteonecrosis of the jaw among bisphosphonate users,” The American Journal of Medicine, vol. 121, no. 6, pp. 475.e3–483.e3, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. H. A. Almăşan, M. Băciuţ, H. Rotaru, et al., “Osteonecrosis of the jaws associated with the use of bisphosphonates. Discussion over 52 cases,” Romanian Journal of Morphology and Embryology, vol. 52, no. 4, pp. 1233–1241, 2011.
  26. C. K. Tong, S. T. Ho, and S. L. Wong, “Osteonecrosis of the jaw after oral bisphosphonate for osteoporosis,” Hong Kong Medical Journal, vol. 16, no. 2, pp. 145–148, 2010. View at Scopus
  27. A. Villa, S. Castiglioni, A. Peretti, et al., “Osteoporosis and bisphosphonate-related osteonecrosis of the jaw bone,” ISRN Rheumatology, vol. 2011, Article ID 654027, 4 pages, 2011. View at Publisher · View at Google Scholar
  28. N. C. Neto, A. D. Bastos, R. A. Chierici-Marcantonio, et al., “Is rheumatoid arthritis a risk factor for oral bisphosphonate-induced osteonecrosis of the jaws?” Medical Hypotheses, vol. 77, pp. 905–911, 2011.
  29. N. Yarom, R. Yahalom, Y. Shoshani, W. Hamed, E. Regev, and S. Elad, “Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome,” Osteoporosis International, vol. 18, no. 10, pp. 1363–1370, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. M. E. Sarasquete, R. García-Sanz, L. Marín et al., “Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytoehrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis,” Blood, vol. 112, no. 7, pp. 2709–2712, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. P. Nicoletti, V. M. Cartsos, P. K. Palaska, et al., “Genomewide pharmacogenetics of bisphosphonate-induced osteonecrosis of the jaw: the role of RBMS3,” Oncologist, vol. 17, no. 2, pp. 279–287, 2012.
  32. J. J. Freiberger, R. Padilla-Burgos, T. McGraw, et al., “What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics,” Journal of Oral and Maxillofacial Surgery, vol. 70, no. 7, pp. 1573–1583, 2012.
  33. Y. D. Kwon, D. W. Lee, B. J. Choi, et al., “Short-term teriparatide therapy as an adjunctive modality for bisphosphonate-related osteonecrosis of the jaws,” Osteoporosis International, vol. 23, no. 11, pp. 2721–2725, 2012.
  34. Y. F. Li and J. Hu, “Parathyroid hormone may be a promising therapy for bisphosphonate-related osteonecrosis of jaw bones,” International Journal of Oral and Maxillofacial Surgery, vol. 42, no. 1, pp. 149–150, 2013.
  35. T. S. Lazarovici, S. Mesilaty-Gross, I. Vered et al., “Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates,” Journal of Oral and Maxillofacial Surgery, vol. 68, no. 9, pp. 2241–2247, 2010. View at Scopus
  36. M. McClung, S. T. Harris, P. D. Miller, et al., “Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday,” The American Journal of Medicine, vol. 126, no. 1, pp. 13–20, 2013.
  37. J. W. Hellstein, R. A. Adler, B. Edwards, et al., “Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs,” The Journal of the American Dental Association, vol. 142, pp. 1243–1251, 2011.
  38. F. S. O'Ryan and J. C. Lo, “Bisphosphonate-related osteonecrosis of the jaw in patients with oral bisphosphonate exposure: clinical course and outcomes,” Journal of Oral and Maxillofacial Surgery, vol. 70, no. 8, pp. 1844–1853, 2012.
  39. B. J. Edwards, J. W. Hellstein, P. L. Jacobsen, S. Kaltman, A. Mariotti, and C. A. Migliorati, “Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: an advisory statement from the American Dental Association Council on Scientific Affairs,” Journal of the American Dental Association, vol. 139, no. 12, pp. 1674–1677, 2008. View at Scopus
  40. S. Otto, K. Sotlar, M. Ehrenfeld, et al., “Osteonecrosis of the jaw as a possible rare side effect of annual bisphosphonate administration for osteoporosis: a case report,” Journal of Medical Case Reports, vol. 5, article 477, 2011.